Literature DB >> 31839269

Osimertinib for leptomeningeal metastases in NSCLC.

Elizabeth Gourd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31839269     DOI： 10.1016/S1470-2045(19)30810-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.

Authors:  Xiaoyang Zhai; Wanhu Li; Ji Li; Wenxiao Jia; Wang Jing; Yaru Tian; Shuhui Xu; Yuying Li; Hui Zhu; Jinming Yu
Journal:  Radiat Oncol       Date:  2021-12-05       Impact factor: 3.481

2.  Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.

Authors:  Xiaoke Liu; Lingzhi Hong; Monique Nilsson; Shawna Marie Hubert; Shuhong Wu; Waree Rinsurongkawong; Jeffery Lewis; Amy Spelman; Jack Roth; Steven Swisher; Yong He; J Jack Lee; Bingliang Fang; John V Heymach; Jianjun Zhang; Xiuning Le
Journal:  Lung Cancer       Date:  2020-09-09       Impact factor: 5.705
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.